Stratagen Quantitative Prostate MRI Platform Pilot Study

Clinicaltrials.gov ID: NCT06985238
db-list-check Status RECRUITING
b-loader Phase NA
b-people Age 40 - 90 Years
b-bullseye-arrow Enrollments 45

Conditions

Prostate Cancer

Summary

The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions.* What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform? * Can the data collected be used to measure quantitative MRI parameters?Participants will:- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.

Locations

1 location Found with status Recruiting

Status

  • RECRUITING

Contact Person

Eligibility Criteria

Inclusion Criteria:

* Subject has a prostate that would be considered for biopsy
* Age 40-90 years
* PSA ≥ 2.5
* Subject has been informed of the nature of the study and has provided written informed consent

Exclusion Criteria:

* Contraindication for MRI
* Prostate biopsy within the previous 12 weeks
* Implant in the pelvis that may cause artifact on MRI (e.g. hip replacement)
* History of prostatectomy or other local prostate cancer therapy (e.g., cryotherapy or brachytherapy), or previous pelvic irradiation
* Currently enrolled in another investigational drug or device study that clinically interferes with this study
* Unable to comply with the study requirements or follow up schedule
* Any condition the Investigator believes would interfere with the intent of this study or would make participation not in the best interest of the subject

Study Plan

Stratagen Quantitative Prostate MRI Platform

  • DEVICE:

    MRI

    Description:

    Will receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.

Outcome Measures

Primary Outcome Measures

Safety: no SAEs attributable to the Stratagen Quantitative Prostate MRI Platform, as determined by participating Investigator according to CTCAE guidelines

Time Frame: Beginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)

u2022 Feasibility: collection of the data necessary to produce measurable quantitative T1 and T2 relaxation times (milliseconds) maps (images) for at least 80% of pixels fully contained within the prostate for at least 80% of subjects

Time Frame: Beginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)

Timeline

  • Last Updated
    October 21, 2025
  • Start Date
    May 22, 2025
  • Today
    December 16, 2025
  • Completion Date ( Estimated )
    October 31, 2026

Similar Trials

light-list-check RECRUITING light-blue-people 18 - 80 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years